Status:
COMPLETED
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
Lead Sponsor:
Ipsen
Conditions:
Intestinal Obstruction
Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether lanreotide 30mg microparticles are effective in the relief of clinical symptoms due to small bowel obstruction in inoperable patients with peritoneal ...
Eligibility Criteria
Inclusion
- digestive obstruction located in the upper part of the gastro-intestinal tract
- digestive obstruction of malignant origin
- peritoneal carcinomatosis confirmed by a CT Scan
- at least two vomiting episodes per day or a presence of a nasogastric suction tube
- inoperable patients
Exclusion
- specific anticancer therapy within the previous 15 days
- signs of bowel perforation
- somatostatin or any analogue as treatment of the bowel obstruction
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00216372
Start Date
September 1 2003
End Date
October 1 2008
Last Update
November 5 2020
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique Universitaire St. LUC
Brussels, Belgium
2
Institut Jules Bordet
Brussels, Belgium
3
Clinique Notre-Dame
Hermalle-sous-Huy, Belgium
4
Centre Hospitalier de Jolimont-Lobbes
La Louvière, Belgium